Telix Pharmaceuticals Limited

TLX

AU000000TLX2

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:12 2025-06-12 am EDT			5-day change	1st Jan Change
25.65 ^AUD	+0.23%		-5.70%	+4.23%

09:07pm	Telix Pharmaceuticals Limited - Analyst/Investor Day
Jun. 11	Telix Pharmaceuticals Announces Gozellix Now Available Nationally In U.S.	RE

Illuccix Prostate Cancer Psma-Pet Imaging Agent Approved In Finland

Published on 04/30/2025 at 02:58

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited - Analyst/Investor Day	09:07pm
Telix Pharmaceuticals Announces Gozellix Now Available Nationally In U.S.	Jun. 11	RE
Telix Launches New Prostate Cancer Imaging Agent, Gozellix, in U.S	Jun. 11	CI
Telix Opens Manufacturing Facility in Japan	Jun. 05	MT
Wedbush Initiates Telix Pharmaceuticals at Outperform With $22 Price Target	Jun. 05	MT
Eckert & Ziegler Has Entered into A Distribution Agreement with Telix Pharmaceuticals Limited for the Prostate Cancer Pet Imaging Agent, Illuccix®, in Germany	Jun. 05	CI
Telix Pharmaceuticals Limited's Illuccix® PSMA-PET Imaging Agent Approves in Portugal	Jun. 04	CI
Telix Says Publication of Thyroid Cancer Therapy Candidate in American Thyroid Association Journal Validates Safety Profile	May. 07	MT
Telix Pharmaceuticals Limited's Illuccix PSMA-PET Imaging Agent Approved in the Czech Republic	May. 05	CI
Illuccix Prostate Cancer Psma-Pet Imaging Agent Approved In Finland	Apr. 30	RE
Telix Pharmaceuticals Limited Announces Illuccix Prostate Cancer PSMA-PET Imaging Agent Approve in Finland	Apr. 30	CI
Telix Pharmaceuticals Secures Marketing Authorization for Prostate Cancer Imaging Agent in France	Apr. 28	MT
Telix Pharmaceuticals Limited Announces Resignation of Anne Whitaker from its Board, Effective 29 April 2025	Apr. 28	CI
Telix Pharmaceuticals Says FDA Requires Additional Clinical Evidence For Tlx101-Cdx Approval	Apr. 27	RE
Telix Pharmaceuticals Says US FDA Ruled New Drug Application for Brain Cancer Imaging Agent 'Cannot be Approved in Current Form'; Shares Down 7%	Apr. 27	MT
Telix Pharmaceuticals Limited - Special Call	Apr. 27
Telix Pharmaceuticals Limited Receives Complete Response Letter from United States Food and Drug Administration for its New Drug Application for TLX101-CDx	Apr. 27	CI
Telix Pharmaceuticals' Revenue Soars 62% in Q1; Fiscal 2025 Guidance Reaffirmed	Apr. 22	MT
ASX Preview: Australian Shares to Open Higher After Wall Street Advances on Trade Hopes	Apr. 22	MT
Sector Update: Health Care Stocks Rise Pre-Bell Tuesday	Apr. 22	MT
Telix Pharmaceuticals Q1 Revenue Increases; 2025 Revenue Outlook Reaffirmed	Apr. 22	MT
Telix Pharmaceuticals Limited Reaffirms Earnings Guidance for the Fiscal Year 2025	Apr. 22	CI
Telix Pharmaceuticals Posts Q1 2025 Unaudited Revenue Of $186 Million	Apr. 22	RE
Telix Pharmaceuticals Limited Reports Unaudited Revenue Results for the First Quarter of 2025	Apr. 22	CI
Telix Pharmaceuticals Limited Announces Preliminary Results from the Phase 2 IPAX-Linz Study of Tlx101	Apr. 17	CI

Chart Telix Pharmaceuticals Limited

Duration

Period

TLX: Dynamic Chart

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Its segments include commercial, product development, medical technologies, and manufacturing services. Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX101, TLX300, TLX66, TLX66-CDx, and TLX090, among others.

Employees

423

Sector

Biotechnology & Medical Research

Calendar

Aug. 20 - Q2 2025 Earnings Release (Projected)

More about the company